|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CASC15 |
Gene summary for CASC15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CASC15 | Gene ID | 401237 |
| Gene name | cancer susceptibility 15 | |
| Gene Alias | CANT | |
| Cytomap | 6p22.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 401237 | CASC15 | AEH-subject1 | Human | Endometrium | AEH | 2.93e-10 | 4.48e-01 | -0.3059 |
| 401237 | CASC15 | AEH-subject2 | Human | Endometrium | AEH | 5.51e-04 | 2.29e-01 | -0.2525 |
| 401237 | CASC15 | AEH-subject3 | Human | Endometrium | AEH | 3.96e-07 | 3.79e-01 | -0.2576 |
| 401237 | CASC15 | AEH-subject4 | Human | Endometrium | AEH | 1.09e-20 | 6.79e-01 | -0.2657 |
| 401237 | CASC15 | EEC-subject1 | Human | Endometrium | EEC | 7.00e-04 | 3.52e-01 | -0.2682 |
| 401237 | CASC15 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 8.71e-07 | -1.02e-01 | -0.1934 |
| 401237 | CASC15 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 4.06e-07 | -1.02e-01 | -0.1917 |
| 401237 | CASC15 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.73e-02 | -1.02e-01 | -0.1916 |
| 401237 | CASC15 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 2.23e-03 | -6.52e-02 | -0.1269 |
| 401237 | CASC15 | LZE7T | Human | Esophagus | ESCC | 7.55e-14 | 7.10e-01 | 0.0667 |
| 401237 | CASC15 | LZE22T | Human | Esophagus | ESCC | 1.76e-06 | 3.75e-01 | 0.068 |
| 401237 | CASC15 | P2T-E | Human | Esophagus | ESCC | 5.03e-37 | 6.85e-01 | 0.1177 |
| 401237 | CASC15 | P4T-E | Human | Esophagus | ESCC | 3.73e-11 | 3.08e-01 | 0.1323 |
| 401237 | CASC15 | P8T-E | Human | Esophagus | ESCC | 1.78e-03 | 9.16e-02 | 0.0889 |
| 401237 | CASC15 | P9T-E | Human | Esophagus | ESCC | 1.06e-03 | 1.68e-01 | 0.1131 |
| 401237 | CASC15 | P10T-E | Human | Esophagus | ESCC | 1.07e-50 | 7.68e-01 | 0.116 |
| 401237 | CASC15 | P11T-E | Human | Esophagus | ESCC | 4.12e-09 | 4.26e-01 | 0.1426 |
| 401237 | CASC15 | P12T-E | Human | Esophagus | ESCC | 1.00e-24 | 4.34e-01 | 0.1122 |
| 401237 | CASC15 | P15T-E | Human | Esophagus | ESCC | 1.60e-14 | 4.29e-01 | 0.1149 |
| 401237 | CASC15 | P16T-E | Human | Esophagus | ESCC | 6.62e-20 | 3.14e-01 | 0.1153 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |